AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling.


Journal

Molecular cancer research : MCR
ISSN: 1557-3125
Titre abrégé: Mol Cancer Res
Pays: United States
ID NLM: 101150042

Informations de publication

Date de publication:
04 2021
Historique:
received: 15 07 2020
revised: 09 11 2020
accepted: 04 12 2020
pubmed: 12 12 2020
medline: 13 1 2022
entrez: 11 12 2020
Statut: ppublish

Résumé

Mutational activation of the PI3K/AKT pathway is among the most common pro-oncogenic events in human cancers. The clinical utility of PI3K and AKT inhibitors has, however, been modest to date. Here, we used CRISPR-mediated gene editing to study the biological consequences of AKT1 E17K mutation by developing an AKT1 E17K-mutant isogenic system in a

Identifiants

pubmed: 33303690
pii: 1541-7786.MCR-20-0623
doi: 10.1158/1541-7786.MCR-20-0623
pmc: PMC8026572
mid: NIHMS1654277
doi:

Substances chimiques

CTNNB1 protein, human 0
beta Catenin 0
AKT1 protein, human EC 2.7.11.1
Proto-Oncogene Proteins c-akt EC 2.7.11.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

573-584

Subventions

Organisme : NCI NIH HHS
ID : R01 CA207244
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA234361
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA221745
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA094060
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA204749
Pays : United States

Informations de copyright

©2020 American Association for Cancer Research.

Références

Breast Dis. 2010;32(1-2):35-48
pubmed: 21778573
Mol Cancer. 2012 Aug 24;11:61
pubmed: 22917467
Sci Rep. 2017 Mar 13;7:44244
pubmed: 28287129
Methods. 2003 Jul;30(3):256-68
pubmed: 12798140
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Proc Natl Acad Sci U S A. 2011 Nov 29;108(48):19204-9
pubmed: 22080605
Cancer Res. 2007 Jan 1;67(1):167-77
pubmed: 17210696
Cancer Res. 2013 Oct 15;73(20):6299-309
pubmed: 23943797
Gut. 2012 Mar;61(3):329-30
pubmed: 22147511
Nat Cell Biol. 2009 Jun;11(6):694-704
pubmed: 19448627
Oncotarget. 2015 Nov 24;6(37):39634-50
pubmed: 26053093
Biomed Res Int. 2014;2014:921564
pubmed: 25197668
Cancer Cell. 2015 Aug 10;28(2):155-69
pubmed: 26267533
J Biol Chem. 2007 Apr 13;282(15):11221-9
pubmed: 17287208
Sci Rep. 2018 Jan 25;8(1):1595
pubmed: 29371630
Mol Cancer Ther. 2012 Apr;11(4):873-87
pubmed: 22294718
Oncogene. 2005 Mar 31;24(14):2375-85
pubmed: 15674322
Cancer Cell. 2018 Sep 10;34(3):427-438.e6
pubmed: 30205045
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
Cancer Discov. 2012 Jan;2(1):56-67
pubmed: 22328975
Mol Cancer Ther. 2016 Jul;15(7):1656-68
pubmed: 27196759
Clin Cancer Res. 2016 Jun 1;22(11):2599-601
pubmed: 26979397
Oncogene. 2010 Apr 22;29(16):2337-45
pubmed: 20101210
J Cell Biol. 2011 Jan 24;192(2):209-18
pubmed: 21263025
Nat Rev Mol Cell Biol. 2010 Jan;11(1):9-22
pubmed: 20027184
Cancer Res. 2016 Mar 15;76(6):1451-62
pubmed: 26759241
Oncogene. 2010 Jul 1;29(26):3845-53
pubmed: 20440266
J Biol Chem. 2006 Apr 14;281(15):9971-6
pubmed: 16476742
J Exp Med. 2011 May 9;208(5):875-83
pubmed: 21518799
Nat Cell Biol. 2011 Mar;13(3):317-23
pubmed: 21336307
Clin Cancer Res. 2013 Apr 1;19(7):1760-72
pubmed: 23287563
Pharmacol Ther. 2017 Apr;172:101-115
pubmed: 27919797
J Clin Oncol. 2017 Jul 10;35(20):2251-2259
pubmed: 28489509
Mol Cell. 2005 Nov 23;20(4):539-50
pubmed: 16307918
J Biol Chem. 2011 May 6;286(18):16218-28
pubmed: 21454711
Oncogene. 2010 Aug 19;29(33):4715-24
pubmed: 20562907
Nat Genet. 2016 Apr;48(4):356-8
pubmed: 26901067
Cancer Discov. 2014 Apr;4(4):405-14
pubmed: 24658082
Sci Signal. 2016 Mar 29;9(421):ra33
pubmed: 27025877
Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4134-9
pubmed: 16537497
Mol Cell. 2010 May 14;38(3):333-44
pubmed: 20471940
Curr Opin Cell Biol. 2005 Oct;17(5):548-58
pubmed: 16098727
Cancer Res. 2004 May 1;64(9):3171-8
pubmed: 15126356
Clin Cancer Res. 2013 Oct 1;19(19):5413-22
pubmed: 23888070
Nat Cell Biol. 2014 Nov;16(11):1092-104
pubmed: 25344754
Nature. 2019 Sep;573(7774):439-444
pubmed: 31485072
Mol Cancer Res. 2019 Sep;17(9):1787-1800
pubmed: 31138602
Mol Cancer Ther. 2015 Nov;14(11):2441-51
pubmed: 26351323
Hum Pathol. 2015 Sep;46(9):1267-74
pubmed: 26170011
EMBO J. 2012 Jun 13;31(12):2714-36
pubmed: 22617422
Cancer Res. 2003 Jan 1;63(1):196-206
pubmed: 12517798
Clin Cancer Res. 2016 Jun 1;22(11):2650-8
pubmed: 26783290
J Cell Biol. 2005 Dec 19;171(6):1023-34
pubmed: 16365168
Nature. 2007 Jul 26;448(7152):439-44
pubmed: 17611497
Nat Rev Drug Discov. 2014 Feb;13(2):140-56
pubmed: 24481312
J Cell Sci. 1999 Apr;112 ( Pt 8):1237-45
pubmed: 10085258

Auteurs

Sizhi Paul Gao (SP)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Amber J Kiliti (AJ)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Kai Zhang (K)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Naresh Vasani (N)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Ninghui Mao (N)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Emmet Jordan (E)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Hannah C Wise (HC)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.

Tripti Shrestha Bhattarai (T)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.

Wenhuo Hu (W)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Madeline Dorso (M)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

James A Rodrigues (JA)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Kwanghee Kim (K)

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.

Aphrothiti J Hanrahan (AJ)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Pedram Razavi (P)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Brett Carver (B)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.

Sarat Chandarlapaty (S)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Jorge S Reis-Filho (JS)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Barry S Taylor (BS)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Weill Medical College of Cornell University, New York, New York.

David B Solit (DB)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. solitd@mskcc.org.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Weill Medical College of Cornell University, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH